(Q46679517)

24 December 2017

title

Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England (English)

1 reference

24 December 2017

author name string

Beate Aurich Barrera

1

1 reference

24 December 2017

Lynda Wilton

2

1 reference

24 December 2017

Scott Harris

3

1 reference

24 December 2017

Saad A W Shakir

4

1 reference

24 December 2017

language of work or name

English

0 references

publication date

31 August 2005

1 reference

24 December 2017

Osteoporosis International

published in

1 reference

24 December 2017

volume

16

1 reference

24 December 2017

issue

12

1 reference

24 December 2017

page(s)

1989-1998

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s00198-005-1986-1

exact match

0 references

cites work

General practice postal surveys: a questionnaire too far?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00198-005-1986-1

Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa

21 January 2018

1 reference

12 December 2020

A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group

1 reference

12 December 2020

Bisphosphonate mechanism of action

1 reference

12 December 2020

Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.

1 reference

12 December 2020

Paget's disease: ocular complications of disodium pamidronate treatment

1 reference

12 December 2020

A Bayesian neural network method for adverse drug reaction signal generation.

1 reference

12 December 2020

Harmonising adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences

1 reference

12 December 2020

Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

1 reference

12 December 2020

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis

1 reference

12 December 2020

An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae

1 reference

12 December 2020

Pharmacovigilance study of alendronate in England

1 reference

12 December 2020

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

12 December 2020

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

12 December 2020

Pamidronate and uveitis

1 reference

12 December 2020

Pamidronate disodium and possible ocular adverse drug reactions

1 reference

12 December 2020

Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.

1 reference

12 December 2020

Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group

1 reference

12 December 2020

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

1 reference

12 December 2020

14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status

1 reference

12 December 2020

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases

1 reference

12 December 2020

Prescription-event monitoring and reporting of adverse drug reactions

1 reference

12 December 2020

Nongranulomatous anterior uveitis associated with alendronate therapy.

1 reference

12 December 2020

Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH

1 reference

12 December 2020

Bisphosphonates: new indications and methods of administration

1 reference

12 December 2020

Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women

1 reference

12 December 2020

Scleritis and other ocular side effects associated with pamidronate disodium

1 reference

12 December 2020

Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review

1 reference

12 December 2020

Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.

1 reference

12 December 2020

Ocular inflammation associated with alendronate therapy

1 reference

12 December 2020

Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study

1 reference

12 December 2020

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

1 reference

12 December 2020

Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women

1 reference

12 December 2020

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

12 December 2020

Bisphosphonates and ocular inflammation

1 reference

12 December 2020

Tolerability and compliance with risedronate in clinical practice

1 reference

12 December 2020

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

12 December 2020

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

1 reference

12 December 2020

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

1 reference

12 December 2020

Episcleritis secondary to risedronate

1 reference

12 December 2020

Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study

1 reference

12 December 2020

10.1007/S00198-005-1986-1

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017